Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, December 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 46 Mendeley

Summary X Facebook

So far, Altmetric has seen 1 public wall post.

Healtheconbot, 13 Dec 2018

#HealthEconJA Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence…